BioNTech SE ((NASDAQ:(BNTX))) shares fell to a low of $237.50 before closing at $238.15. Intraday shares traded counted 4.36 million, which was -60.17% lower than its 30-day average trading volume of 2.72M. (BNTX)’s previous close was $233.29 while the outstanding shares total 243.12M. The firm has a 12-month trailing P/E ratio of 43.20. The stock’s Relative Strength Index (RSI) is 72.67, with weekly volatility at 5.61% and ATR at 13.96. The (BNTX) stock’s 52-week price range has touched low of $46.55 and a $235.00 high. The stock traded higher over the last trading session, gaining 2.08% on 06/07/21.
Investors have identified the Biotechnology company BioNTech SE as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $53.09 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For (BNTX), the company has in raw cash 1.07 billion on their books with 21.7 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 4.26 billion total, with 1.58 billion as their total liabilities.
(BNTX) were able to record -401.46 million as free cash flow during the 08/09/2021 quarter of the year, this saw their quarterly net cash flow reduce by -384.23 million. In cash movements, the company had a total of -375.3 million as operating cash flow.
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/09/2021 quarter of the year, BioNTech SE recorded a total of 2.47 billion in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 98.76% coming in sequential stages and their sales for the 08/09/2021 quarter increasing by 83.98%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 281.02 million trying to sell their products during the last quarter, with the result yielding a gross income of 2.19 billion. This allows shareholders to hold on to 243.12M with the recently reported earning now reading 5.59 cents per share. This is a figure that compared to analyst’s prediction for their 08/09/2021 (5.29 cents a share).
Having a look at the company’s valuation, the company is expected to record 25.05 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on (BNTX) sounds very interesting.
Is the stock of (BNTX) attractive?
In the last 6 months, insiders have changed their ownership in shares of company stock by 1.18%.
4 out of 13 analysts covering the stock have rated it a Buy, while 8 have maintained a Hold recommendation on BioNTech SE. 0 analysts has assigned a Sell rating on the (BNTX) stock. The 12-month mean consensus price target for the company’s shares has been set at $195.72.